[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Henri Becquerel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":419},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,46,78,104,132,160,184,208,232,252,272,298,322,346,371,396],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640044","phase-2-evaluation-of-68gaga-nota-anti-her2-sdab-petct-for-predicting-pathological-complete-response-after-neoadjuvant-chemotherapy-in-her2-positive-early-breast-cancer-100640044",false,"NCT07593976","Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET\u002FCT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer","Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET\u002FCT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer (GATHER): a Study Protocol for a Monocentric, Prospective, Interventional, Phase 2, Imaging Biomarker Trial.","GATHER","Inclusion Criteria:\n\n* Female aged 18 years or older\n* Histologically proven HER2-positive early breast cancer, defined as IHC 3+ or IHC 2+ with ISH amplification\n* Indication for neoadjuvant chemotherapy combined with anti-HER2 targeted therapy followed by surgery, as determined by a multidisciplinary tumor board\n* ECOG performance status of 0 or 1\n* Affiliated to or beneficiary of a social protection scheme\n* Written informed consent signed prior to any study-specific procedure\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n\n  * Patient not treated with curative intent\n  * History of ipsilateral breast cancer treated by surgery and\u002For radiotherapy\n  * Lobular histology\n  * Known contraindication or hypersensitivity to \\[68Ga\\]Ga-NOTA-anti-HER2-sdAb or any of its radiopharmaceutical excipients\n  * Known contraindication or hypersensitivity to \\[18F\\]F-FDG or any of its radiopharmaceutical excipients\n  * Concurrent enrollment in another clinical trial evaluating radiopharmaceuticals\n  * Patient under guardianship, curatorship, or judicial protection\n  * Patient deprived of liberty\n  * Inability to understand the study or comply with trial constraints due to linguistic, psychological, or geographical barriers","FEMALE","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The GATHER trial aim to evaluate the diagnostic performance of \\[68Ga\\]Ga-NOTA-anti-HER2-sdAb PET\u002FCT in predicting pCR following neoadjuvant chemotherapy. This study is part of the development of new functional, non-invasive approaches with the aim of offering personalized therapeutic approaches.",[27],"Breast Cancer",[29,30,31,32],"early breast cancer","Positron emission tomography","Gallium radioisotopes","pathological complete response","NOT_YET_RECRUITING","2026-05-12",{"date":36,"type":37},"2026-05-18","ACTUAL",{"date":39,"type":21},"2026-09-01",{"date":41,"type":21},"2028-03-01",{"name":43,"class":44},"Centre Henri Becquerel","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100637594","impact-of-body-composition-on-dosimetry-of-177lu-psma-radioligand-therapy-100637594","NCT07587814","Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy","Impact de la Composition Corporelle Sur la dosimétrie de la radiothérapie Interne vectorisée au 177Lu-PSMA","COCORIVO","Inclusion Criteria:\n\n* Signed informed consent\n* Male, age \\>= 18 years\n* Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment\n* PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET\u002FCT\n* Affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)\n* Patient under legal protection (tutelle, curatelle, sauvegarde de justice)","MALE",{"count":56,"type":21},100,[58],"NA","COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.",[61,62],"Carcinoma","Castration Resistant Prostatic Neoplasms",[64,65,66,67,68,69],"Lutetium-177","PSMA","Body composition","Dosimetry","Radioligand therapy","Prostate cancer","2026-05-11",{"date":72,"type":37},"2026-05-14",{"date":74,"type":21},"2026-09",{"date":76,"type":21},"2029-06",{"name":43,"class":44},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100636031","feasibility-study-on-the-implementation-of-a-supervised-home-based-adapted-physical-activity-program-for-patients-with-head-and-neck-cancer-100636031","NCT07560397","Feasibility Study on the Implementation of a Supervised, Home-based Adapted Physical Activity Program for Patients With Head and Neck Cancer","Feasibility Study on the Implementation of a Supervised, Home-based Adapted Physical Activity Program During the Preoperative Phase for Patients With Head and Neck Cancer","PREPACHIR ORL","Inclusion Criteria:\n\n* surgery requiring the placement of a covering flap)\n* Medical prescription of adapted physical activity\n* A period of more than 2 weeks between the announcement of surgery and the surgery itself\n\nExclusion Criteria:\n\n* Absolute contraindications to physical activity\n* Pregnant or breastfeeding women\n* Patients who, for any reason, are unable to understand the study or comply with the trial requirements (language, psychological, or geographical barriers, etc.)","ALL",{"count":88,"type":21},66,[58],"Head and neck cancers are the seventh most common type of cancer worldwide. The standard of care is surgical removal of the tumor, often accompanied by simultaneous reconstruction of the affected structures.\n\nEnhanced post-surgical rehabilitation programs are offered to promote early recovery of functional abilities; they are applicable to all patients and all surgical specialties. Studies have shown a very significant benefit of physical activity prior to surgery in the context of cancers of the digestive or thoracic systems. Multimodal programs that incorporate nutritional and psychosocial factors and include physical exercise have been shown to improve postoperative mobility and physical activity levels in patients with colorectal, gastrointestinal, lung, and prostate cancers.\n\nOur hypothesis is based on the premise that implementing an exercise program during the preoperative period could promote a return to optimal functional capacity, reduce the incidence of postoperative pulmonary complications, and lower overall morbidity. Furthermore, we believe that the proposed support would encourage greater patient involvement in their care journey starting in the preoperative period and raise their awareness of the importance of postoperative mobilization. Early patient involvement would thus help develop their sense of self-efficacy and promote behavioral change toward a more active lifestyle suited to their health status. Consequently, maintaining physical activity after surgery and in the post-cancer period-recognized as a factor in secondary and tertiary prevention-would be encouraged.",[92],"Head & Neck Cancer",[94,95],"Physical activity program","home-based","2026-04-24",{"date":98,"type":37},"2026-05-01",{"date":100,"type":21},"2026-06-01",{"date":102,"type":21},"2028-10-01",{"name":43,"class":44},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":86,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":45},"100631368","benefits-of-formalized-care-support-program-following-acute-leukemia-diagnosis-100631368","NCT07499765","Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis","Benefits of Formalized Care Support Program Following an Annoucement of Acute Leukemia Diagnosis","ANX-LA","Inclusion Criteria:\n\n* informed consent signed\n* medical confirmation of acute leukemia diagnosis\n* age equal of superior to 26 years and under 80 years\n* confirmed diagnosis not yet treated\n* hospitalization at Centre Henri Becquerel\n* member or beneficiary of a social security\n\nExclusion Criteria:\n\n* -Patient unable to understand the study for any reason or to comply with the trial's requirements\n* Patient in relapse of acute leukemia\n* Patient diagnosed with acute myeloid leukemia 3\n* History of cancer within the 5 years preceding the year of study enrollment\n* Alcohol and drug abuse\n* Inclusion in another therapeutic trial that prevents further enrollment in a trial evaluating quality of life or psychological well-being\n* Diagnosed psychiatric illness\n* Patient under guardianship, curatorship, or legal protection","26 Years","80 Years",{"count":115,"type":21},110,[58],"The purpose of this study is to determine the impact on anxiety between patients with a period of care support following their announcement of an acute leukemia (AL) diagnosis and patients without this accompaniment.",[119],"Acute Leukemia",[121,122,123],"acute leukemia","anxiety","care support program","RECRUITING",{"date":126,"type":37},"2026-04-29",{"date":128,"type":21},"2026-03-30",{"date":130,"type":21},"2029-04-15",{"name":43,"class":44},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},"100607607","impact-of-patient-reported-outcomes-for-symptom-monitoring-in-patients-followed-for-head-and-neck-squamous-cell-carcinoma-hnscc-100607607","NCT07190755","Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)","Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Curative Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC) With Radiotherapy or Chemoradiotherapy","WEBNECK","Inclusion Criteria:\n\n* Patient aged over 18 and under 75 years WHO score \\\u003C 2,\n\n  * Treated for localised heand and neck cancer of the squamous cell carcinoma type for which curative treatment has been chosen and receiving radiotherapy or radio-chemotherapy exclusively or as an adjuvant with the aim of cure\n  * Having signed the informed consent form,\n  * Affiliated with or beneficiary of a social protection scheme,\n  * Access to a smartphone or the internet,\n\nExclusion Criteria:\n\n* History of other neoplastic disease less than 2 years ago or progressive disease,\n* History of ENT radiotherapy,\n* Pregnant or breastfeeding women,\n* Protected adults (under guardianship, curatorship or judicial protection),\n* Patients participating in a therapeutic study,\n* Patients unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological or geographical issues, etc.), patients with blindness preventing the use of the medical telemonitoring solution in oncology.","75 Years",{"count":142,"type":21},192,[58],"The use of digital strategies to systematically monitor patients' symptoms in clinical settings allows problems to be detected at an early stage before they worsen or lead to complications. In this study, the hypothesis is that the proportion of patients with a weight loss of at least 5% between before radiotherapy\u002Fradiochemotherapy and 3 months after treatment would be lower with optimised care thanks to remote monitoring using a medical telemonitoring solution in oncology.",[146],"Head and Neck Squamous Cell Carcinoma HNSCC",[148,149,150],"head and neck squamous cell carcinoma","symptoms monitoring","web monitoring","2025-12-29",{"date":153,"type":37},"2025-12-30",{"date":155,"type":37},"2025-10-15",{"date":157,"type":21},"2030-06-01",{"name":43,"class":44},2,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":45},"100583698","radiological-prediction-of-response-to-neoadjuvant-chemoimmunotherapy-for-triple-negative-breast-cancer-100583698","NCT06879704","Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer","Quadrimodal Radiological Prediction (Ultrasound, Angiography\u002FMammography, Magnetic Rsonance Imaging, Positron Emission Tomography-computed Tomgraphy Scan) of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer","PRECISION","Inclusion Criteria:\n\n* Signed informed consent\n* Patient with histologically proven TNBC\n* Indication for neo-adjuvant chemo-immunotherapy treatment\n* Age between 18 and 75\n* Affiliated or beneficiary of a social protection scheme\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Contraindication to immunotherapy\n* Inflammatory breast cancer (T4d)\n* Metastatic patients\n* Allergies to iodine or gadolinium\n* Patient with an augmentation prosthesis (for angiography\u002Fmammography)\n* Claustrophobic patients\n* Renal contraindication to contrast products according to SFR-CIRTACI\n* Ferromagnetic material\n* Uncontrolled diabetes (blood glucose \\>10 mmol\u002FL)\n* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).\n* Patient under guardianship, curatorship or safeguard of justice",{"count":169,"type":21},115,[58],"The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.",[173],"Triple Negative Breast Cancer",[173,175,176],"chemo-immunotherapy","radiological prediction",{"date":178,"type":37},"2026-01-02",{"date":180,"type":37},"2025-05-28",{"date":182,"type":21},"2029-11-28",{"name":43,"class":44},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":45},"100550705","dynamic-68ga-psma-and-18f-fdg-petct-analysis-prior-to-177lu-psma-100550705","NCT06450548","Dynamic 68Ga-PSMA and 18F-FDG PET\u002FCT Analysis Prior to 177Lu-PSMA","Dynamic 68Ga-PSMA and 18F-FDG PET\u002FCT Analysis of Metastatic Prostatic Adenocarcinomas Prior to 177Lu-PSMA Treatment","PYPET","Inclusion Criteria:\n\n* Signed informed consent.\n* Progressive metastatic castration-resistant prostate adenocarcinoma, which has been treated with taxane chemotherapy and at least one anti-androgen hormone therapy.\n* Evaluated by 18F-FDG and 68Ga-PSMA PET\u002FCT prior to potential treatment with 177Lu-PSMA.\n* Affiliated with or beneficiary of a social protection scheme.\n* WHO stage 0 or 1.\n\nExclusion Criteria:\n\n* Patients unable to understand the study for any reason or comply with the trial requirements (due to language barriers, psychological issues, geographical constraints, etc.).\n* Patients unable to undergo the examinations and\u002For maintain a prolonged lying position (due to back pain, etc.).",{"count":193,"type":21},60,[58],"Prostate cancer is a significant health issue, representing 21.8% of male cancer cases in France with over 449,000 new cases in 2018. It's the cause of 10% of cancer deaths in Europe.\n\nThe PSMA is a target for mCRPC treatment, with therapies like 177Lu-PSMA-617 delivering radiation to cancer cells. The Vision study showed that 177Lu-PSMA-617, combined with standard care, improved survival rates significantly compared to standard care alone.The French ANSM authorized 177Lu-PSMA-617 for mCRPC under certain conditions. Patients must have histologically confirmed mCRPC, be progressive despite treatment, and have PSMA-positive imaging.\n\nImaging assessments include PSMA PET\u002FCT and 18F-FDG PET\u002FCT to identify FDG-positive and PSMA-negative sites, which are associated with a poorer prognosis.\n\nParametric analysis using dynamic PET could improve lesion characterization, aiding in treatment decisions. This is the focus of the PyPET study.\n\nThe main objective focuses on a comparative analysis of data from dynamic parametric analysis (metabolic influx rate Ki, volume of distribution Vd) and static analysis (standard at 1 hour) using 18F-FDG and 68Ga-PSMA PET\u002FCT for diagnosing metastases, especially in the liver, lymph nodes, and bones. It aims to assess the effectiveness of these imaging techniques in accurately identifying metastatic sites.",[197],"Prostate Cancer Metastatic",[199,200,201],"prostate cancer","68GA-PSMA","parametric acquisition",{"date":178,"type":37},{"date":204,"type":37},"2025-03-05",{"date":206,"type":21},"2028-03-05",{"name":43,"class":44},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":45},"100505211","influence-of-body-composition-on-chemotherapy-outcomes-in-localized-breast-cancer-100505211","NCT05858398","Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer","Influence of Body Composition, Total Body Fat and Body Mass Index on the Pharmacokinetics of Docetaxel in Localized Breast Cancer","FATTAX","Inclusion Criteria:\n\n* Woman older than\n* Early breast cancer\n* CT-scan of less than 3 months, including L3 level\n* Indication of docetaxel at 100 mg\u002Fm² as adjuvant CT\n\nExclusion Criteria:\n\n* HER2 amplified or triple negative tumors\n* Pregnant or breastfeeding women\n* Patients under guardianship or curatorship\n* Concomitant administration of another cytotoxic drug or targeted therapy\n* Psychosocial disorder\n* Administration of another cytotoxic drug or targeted therapy within 20 days prior to blood collection",{"count":217,"type":21},48,[58],"The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer",[27],[222,223,224,225],"breast cancer","body composition","docetaxel","pharmacokinetics",{"date":178,"type":37},{"date":228,"type":37},"2023-10-25",{"date":230,"type":21},"2027-05-02",{"name":43,"class":44},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":45},"100480954","benefit-of-paramedical-care-in-accompanying-caregivers-of-patients-that-had-surgery-for-an-head-and-neck-invasive-cancer-100480954","NCT05542706","Benefit of Paramedical Care in Accompanying Caregivers of Patients That Had Surgery for an Head and Neck Invasive Cancer","AIDORL","Inclusion Criteria Patients :\n\n* Age between 18 and 85 years old\n* ECOG ≤ 2\n* Patient diagnosed with an head and neck squamous-cell carcinoma, stage T2-T4\u002FN+, non-metastatic, localised at larynx, pharynx, oropharynx, oral cavity or maxillary, needing curative surgery, with indication of radiotherapy after surgery, in accordance to decision of the regular multidisciplinary meetings in cancerology\n* No ongoing measure of corrective justice for the patient\n* Informed consent form signed\n* Patient covered by health system\n\nExclusion Criteria:\n\n* Patient scheduled for surgery after radiotherapy or for surgery on site already irradiated\n* Patient or caregiver that do not agree to participate in the study (the pair patient-caregiver is needed)\n* History of psychological or sensorial disorder or anomaly that can prevent the patient from understanding the conditions for study participation","85 Years",{"count":241,"type":21},76,[58],"Head and Neck invasive cancer usually requires surgery that is associated with modifications of the body structure of patient regarding breathing, eating and communication. These modifications are correlated with an important loss of autonomy in patients. During the study, while the patient is hospitalised after the surgery, the paramedical team will train the caregiver of the patient from experimental group a new dimension of autonomy in order to assure a safe return home. The level of learning depends on each caregiver and patient; therefore, an adapted training is provided.\n\nThis study evaluates the impact of paramedical care in accompanying caregivers of patients that had surgery for an ENT invasive cancer, by comparing the experimental group (paramedical care) to the standard group (standard care).\n\nThe hypothesis of the study is that a benefit will be seen in the experimental group, by reducing the caregiver burden, improving the quality of life of patients and lowering the rate of hospitalisations and prolonged hospitalisations in these patients.",[245],"Head and Neck Cancer",{"date":178,"type":37},{"date":248,"type":37},"2022-10-31",{"date":250,"type":21},"2027-10-31",{"name":43,"class":44},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":45},"100450491","interest-of-parametric-positron-emission-imaging-in-the-diagnosis-of-infections-on-cardiac-valve-prosthesis-100450491","NCT05146180","Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis","Interest of Parametric Positron Emission Computed Tomography Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis : PARAVA Study","PARAVA","Inclusion Criteria:\n\n* Age superior to18 years,\n* Effective contraception for women of childbearing age or negative pregnancy test on the day of the exam\n* Good general condition. WHO ≤ 1\n* Suspicion of endocarditis on a prosthetic heart valve implanted more than 3 months ago\n* Labeled polynuclear scintigraphy performed within a maximum of 15 days before positron emission computed tomography\n* Standard positron emission computed tomography planned as part of the extension assessment\n* Informed and signed consent before any specific study procedure.\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Presence of an active cancer in the previous three years\n* Pregnancy or breastfeeding\n* Poorly controlled diabetic patients\n* Protected adults (under guardians or curators)\n* Impossible decubitus (orthopnea, ...),\n* Hypersensitivity to FDG or to one of the excipients of the radiopharmaceutical.",{"count":261,"type":21},30,[58],"The objective of this study is to determine if early parametric positron emission computed tomography is useful to diagnose cardiac prosthetic valve infections.",[265],"Endocarditis",{"date":178,"type":37},{"date":268,"type":37},"2022-02-24",{"date":270,"type":21},"2027-03-01",{"name":43,"class":44},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":140,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":297},"100403063","optimised-early-management-of-squamous-cell-carcinoma-of-the-head-and-neck-cancer-100403063","NCT04528420","Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer","Evaluation of Optimised Early Management in the Context of Radiochemotherapy for Curatively Treated Squamous Cell Carcinoma of the Head and Neck","OPTINECK","Inclusion Criteria:\n\n* Male or female, over 18 and under 75 years of age,\n* Worl Health Organisation score \\\u003C 2,\n* Treatment for a localized squamous cell carcinoma of the head and neck for which a curative treatment by concomitant post-operative radiochemotherapy based on cisplatin is retained,\n* Having signed the informed consent,\n* Affiliate or beneficiary of a social protection scheme.\n\nExclusion Criteria:\n\n* History of other neoplastic disease less than 2 years old or progressive,\n* History of radiotherapy for head and neck cancer,\n* Contraindications to cisplatin,\n* Pregnant or breastfeeding woman,\n* Protected major (under guardianship or curatorship),\n* Patient participating in a therapeutic study\n* Patient unable to understand the study for any reason or to comply with the constraints of the trial",{"count":281,"type":21},138,[58],"Post-operative concomitant radiochemotherapy is a treatment that is difficult to achieve for several reasons. First of all, and by definition, these patients have had recent surgery, most often accompanied by several weeks of hospitalization and weight loss. In addition, the functional recovery of feeding capacity is not always complete at the time of the start of irradiation. In addition, concomitant radiochemotherapy is responsible for very frequent radiomucitus which alters the feeding capacity of patients during treatment.\n\nIn total, the rate of complete radiochemotherapy (3 cures of cisplatin administered) varies from 50 to 70% depending on the studies, which were carried out in selected populations within the framework of an experimental clinical trial and without distinguishing between positive and negative Human Papilloma tumours . In our experience, in a population with a very high preponderance of non-Human Papilloma-related tumours and not selected by participation in an experimental trial, complete radiochemotherapy is only possible in about 40% to 50% of cases.However, the amount of cisplatin actually administered is correlated with overall survival. Therefore, it is logical to assume that increasing the number of patients receiving full treatment may result in increased survival.\n\nWhile the need for nutritional care during radiotherapy is clearly established, its modality remains debated. Recently, a randomised study of 159 patients treated by radiotherapy (or radiochemotherapy) showed that the simple systematic prescription of oral food supplements (500 kcal\u002Fd) in addition to the usual dietary advice was associated with a lesser reduction in weight at the end of radiotherapy (main objective) but also with an improvement in the tolerance of the treatments. Overall, nutritional management during treatment varies greatly, ranging from simple dietary monitoring to prophylactic gastrostomy and the insertion of a nasogastric tube on demand during treatment. This heterogeneity of management found in the literature is also observed at the regional level. This project will also make it possible to propose a harmonized support strategy at the inter-regional level.",[285],"Squamous Cell Carcinoma of Head and Neck",[287,288,289,290],"radiochemotherapy","nutrition","support care","early management",{"date":178,"type":37},{"date":293,"type":37},"2020-11-26",{"date":295,"type":21},"2028-06-01",{"name":43,"class":44},7,{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":45},"100614897","performance-of-18f-fdg-micro-pet-ct-in-the-assessment-of-surgical-margins-in-head-and-neck-cancer-100614897","NCT07285564","Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer","TEP Margins","Inclusion Criteria:\n\n* Signed informed consent\n* Adult, male or female, aged 18 or over\n* Patient with a malignant tumor of the oral cavity, oropharynx, hypopharynx, larynx, sinuses, or salivary glands, regardless of lymph node status (any N) M0, operable\n* Member or beneficiary of a social security plan\n\nExclusion Criteria:\n\n* Child-Pugh C liver failure\n* Patients under guardianship, conservatorship, or legal protection\n* Patients deprived of their liberty\n* Pregnant or breastfeeding women\n* Hypersensitivity to 18F-FDG or any of its excipients (ethanol or water for injection)\n* Uncontrolled diabetes\n* Moderate to end-stage renal failure, stage IIIB to V (glomerular filtration rate less than 44 mL\u002Fmin\u002F1.73 m²)\n* Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, or geographical issues).",{"count":306,"type":21},10,[58],"The purpose of this study is to evaluate the diagnostic performance of 18F-FDG micro-PET-CT in malignant Head and neck cancer compared to definitive histological analysis (gold standard).",[92],[311,312,313],"Margins","microPET\u002FCT","specimen","2025-12-02",{"date":316,"type":37},"2025-12-16",{"date":318,"type":37},"2025-11-07",{"date":320,"type":21},"2026-06-15",{"name":43,"class":44},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":159},"100612925","multimodal-prediction-of-response-to-chemoradiotherapy-for-squamous-cell-carcinoma-of-the-head-and-neck-100612925","NCT07259915","Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck","MULTINECK","Inclusion Criteria:\n\n* Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)\n* With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)\n* Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg\u002Fm2 every 3 weeks or 40 mg\u002Fm2 weekly)\n* Regardless of p16 status\n* Affiliated with or covered by a social security system\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)\n* Primary squamous cell carcinoma of the lymph nodes\n* History of radiotherapy to the head and neck region\n* Radiochemotherapy not based on the use of cisplatin\n* Pregnant or breastfeeding women\n* History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm)\n* Contraindication to MRI, CT, or PET\u002FCT\n* Allergy or contraindication to iodine, gadolinium, or 18F-FDG\n* Uncontrolled diabetes (fasting blood glucose greater than 12 mmol\u002Fl)\n* Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.)\n* Patients under guardianship or conservatorship\n* Patients deprived of their liberty by judicial or administrative decision\n* Patients undergoing psychiatric care that renders them incapable of giving their consent\n* Patients admitted to a health or social care facility for purposes other than research",{"count":330,"type":21},152,[58],"The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.",[334],"Squamous Cell Cancer of Head and Neck (SCCHN)",[336,337,338],"multimodal approach","CT DNA","Resonance Magnetic Imaging","2025-11-21",{"date":314,"type":37},{"date":342,"type":21},"2025-12-01",{"date":344,"type":21},"2030-08-01",{"name":43,"class":44},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":370},"100595180","feasibility-of-organoids-in-routine-clinical-practice-for-molecular-analysis-of-the-gliovascular-niche-in-patients-with-primary-brain-tumors-100595180","NCT07029100","Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.","ORGA-GLIO","Inclusion Criteria:\n\n* Patient, male or female, adult (age ≥ 18 years),\n* Suspected of having a high-grade glioma based on preoperative multimodal MRI,\n* With an indication for tumor resection surgery,\n* And in a clinical condition suitable to undergo adjuvant treatment consisting of radiotherapy (normo- or hypo-fractionated) combined with temozolomide, with or without low-frequency electric fields (Tumor-Treating Fields®).\n\nExclusion Criteria:\n\n* Current tumor pathology or history of tumor pathology in remission for less than 2 years\n* Pregnant or breastfeeding women,\n* Patients unable to understand the study for any reason or unable to comply with trial requirements (language barriers, psychological or geographical issues, etc.).",{"count":261,"type":21},[58],"The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection in patients with newly diagnosed glioblastoma.",[357],"Glioblastoma",[359,360,361],"glioblastoma","organoide","molecular analysis","2025-06-18",{"date":364,"type":37},"2025-06-19",{"date":366,"type":21},"2025-07-01",{"date":368,"type":21},"2029-07-01",{"name":43,"class":44},3,{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":45},"100549878","contribution-of-the-veriton-ct-camera-in-prostate-bone-radiostereotaxy-100549878","NCT06439784","Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy","Contribution of 99mTc-HDP Whole-body SPECT\u002FCT Imaging by VERITON-CT CZT Camera in Stereotactic Radiotherapy Treatment of Bone Metastases of Prostate Cancer","VERIOS","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Good general health WHO ≤ 1\n* Informed and signed consent prior to any specific study procedure.\n* Patient affiliated to the social security system\n* Bone metastases from prostate cancer\n* Indication for bone stereotactic radiotherapy\n\nExclusion Criteria:\n\n* Presence of active cancer in the previous three years\n* Protected adults (under guardianship or curatorship)\n* Unable to undergo medical monitoring for geographical, social or psychological reasons\n* Unable to decubitus (orthopnea, etc.),\n* Hypersensitivity to HDP or to one of the excipients of the radiopharmaceutical.\n* History of radiotherapy of the volume to be treated by stereotaxy.",{"count":261,"type":21},[58],"Stereotactic radiotherapy enables bone metastases to be treated with highly precise irradiation beams, enabling small targets to be irradiated. Planning requires the use of cross-sectional imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). Bone scintigraphy with Tc99m-labelled biphosphonates (T1\u002F2=6h) is indicated in the extension assessment of prostate cancers. Thanks to the advent of single-photon emission computed tomography (SPECT) based on CZT detectors; whole-body SPECT is now compatible with clinical constraints. We propose to study the value of using whole-body SPECT for planning stereotactic radiotherapy of metastatic prostate cancer. This is a prospective, single-center, non-randomized study involving 30 patients. Patients will benefit from routine examinations (CT scan, MRI) including a bone SPECT\u002FCT in treatment position performed on the VERITON-CT (Spectrum Dynamics, Haifa, Israel). Planning based on whole-body SPECT images will be carried out remotely from the patient's point of care. The examination will be interpreted by the nuclear physician, and planning will be based on the dosimetric CT scanner, as in standard management. Virtual replanning will be carried out at distance from treatment, incorporating SPECT imaging. Treatment plans with and without SPECT will be compared quantitatively and qualitatively. The feasibility of SPECT imaging in the treatment position will be assessed, enabling lesion location imaging and dosimetric scanning to be performed in a single examination. All therapeutic management and clinical follow-up will be carried out as part of routine care.",[383],"Prostatic Cancer",[385,386,387],"whole body SPECT\u002FCT","bone scintigraphy","stereotaxic bone radiation therapy","2024-05-28",{"date":390,"type":37},"2024-06-03",{"date":392,"type":21},"2024-06-15",{"date":394,"type":21},"2027-06-15",{"name":43,"class":44},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":159},"100425820","circulating-tumor-dna-in-primary-mediastinal-large-b-cell-lymphoma-pmbl-100425820","NCT04824950","Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)","CAMIL","Inclusion Criteria:\n\n* Patient over 18 years of age,\n* Suffering from a diffuse primary B lymphoma of the mediastinum, newly diagnosed locally on a biopsy with anatomopathological analysis according to the recommendations of the WHO 2016 classification of hematological malignancies,\n* All stages (I-IV)\n* All IPI scores (0-5)\n* With mediastinal involvement,\n* Untreated (apart from emergency corticosteroid therapy less than 2mg\u002Fkg\u002Fday for 7 days),\n* Treatment with R-CHOP-14 or R-ACVBP with PET-CT guided strategy (delta SUVmax) to be initiated,\n* Tumor fixation above liver background on pre-treatment FDG PET\u002FCT\u002FCT (Deauville score ≥4),\n* Having signed the informed consent prior to any study procedure\n* Affiliated or beneficiary of a social protection plan.\n\nExclusion Criteria:\n\n* Patient who has already started chemotherapy treatment,\n* Contraindication to FDG PET-CT,\n* No mediastinal involvement,\n* Positive HIV serology,\n* Positive hepatitis B or C serology with positive viral load,\n* Protected adult (under guardianship or curatorship),\n* Pregnant or breastfeeding women,\n* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).",{"count":404,"type":21},87,[58],"The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.",[408],"Primary Mediastinal Large B-cell Lymphoma",[408,410,411],"Circulating tumor DNA","Next Generation sequencing","2021-03-29",{"date":414,"type":37},"2021-04-01",{"date":416,"type":21},"2021-03-22",{"date":41,"type":21},{"name":43,"class":44},""]